GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » EV-to-FCF

AEterna Zentaris (AEterna Zentaris) EV-to-FCF : 1.41 (As of May. 01, 2024)


View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AEterna Zentaris's Enterprise Value is $-24.24 Mil. AEterna Zentaris's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-17.14 Mil. Therefore, AEterna Zentaris's EV-to-FCF for today is 1.41.

The historical rank and industry rank for AEterna Zentaris's EV-to-FCF or its related term are showing as below:

AEZS' s EV-to-FCF Range Over the Past 10 Years
Min: -20.53   Med: -0.19   Max: 15.79
Current: 1.43

During the past 13 years, the highest EV-to-FCF of AEterna Zentaris was 15.79. The lowest was -20.53. And the median was -0.19.

AEZS's EV-to-FCF is ranked better than
58.57% of 391 companies
in the Biotechnology industry
Industry Median: 4.47 vs AEZS: 1.43

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), AEterna Zentaris's stock price is $1.95. AEterna Zentaris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.410. Therefore, AEterna Zentaris's PE Ratio for today is At Loss.


AEterna Zentaris EV-to-FCF Historical Data

The historical data trend for AEterna Zentaris's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris EV-to-FCF Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 -0.57 2.38 2.56 1.43

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 2.17 1.87 1.75 1.43

Competitive Comparison of AEterna Zentaris's EV-to-FCF

For the Biotechnology subindustry, AEterna Zentaris's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's EV-to-FCF falls into.



AEterna Zentaris EV-to-FCF Calculation

AEterna Zentaris's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-24.244/-17.137
=1.41

AEterna Zentaris's current Enterprise Value is $-24.24 Mil.
AEterna Zentaris's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AEterna Zentaris  (NAS:AEZS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

AEterna Zentaris's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.95/-3.410
=At Loss

AEterna Zentaris's share price for today is $1.95.
AEterna Zentaris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


AEterna Zentaris EV-to-FCF Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.